Detalhe da pesquisa
1.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1075-86, 2015 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467591
2.
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Gastroenterology
; 147(2): 366-76.e6, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24727022
3.
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
J Hepatol
; 61(2): 200-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24747798
4.
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Gastroenterology
; 145(5): 1035-1044.e5, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23924660
5.
Multiplexed serologic assay for nine anogenital human papillomavirus types.
Clin Vaccine Immunol
; 17(5): 818-27, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20237197